Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES versus TAVIST 1.
CETIRIZINE HYDROCHLORIDE HIVES vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist of histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and gastrointestinal tract.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
10 mg orally once daily; maximum 10 mg per day.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8–11 hours in healthy adults (mean ~8.3 h). In renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 20–30 hours, requiring dose adjustment.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Approximately 70% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion, with about 10% excreted in feces. Biliary elimination is minimal.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine
Antihistamine